Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity:: Evidence of variabilities in levels of virion-associated RT

被引:17
作者
Lerma, JGG
Yamamoto, S
Gómez-Cano, M
Soriano, V
Green, TA
Busch, MP
Folks, TM
Heneine, W
机构
[1] Ctr Dis Control & Prevent, HIV Retrovirus Dis Branch, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA
[2] Inst Salud Carlos III, Ctr Nacl Invest Clin, Serv Enfermedades Infecciosas, Madrid, Spain
[3] Irwin Mem Blood Ctr, San Francisco, CA 94142 USA
关键词
D O I
10.1086/515272
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Virus load based on levels of functional reverse transcriptase (RT) was measured in plasma from 50 human immunodeficiency virus (HIV) type 1-infected persons, in 87 samples from 10 HIV-1 seroconversion panels, and in 100 uninfected persons by use of Amp-RT, an ultrasensitive RT assay, Of the 50 clinical samples, 38 (76%) were Amp-RT positive, while all uninfected controls were negative. Pearson's correlation coefficient of RNA and RT levels was .73 for all samples, .86 for seroconversion samples, and .49 for clinical samples. Calculated ratios of RT activity to virion RNA varied widely during both early and late stages of infection. Mean RT:RNA ratios in 8 seroconversion panels and in 12 (34.3%) of 35 individual clinical samples were significantly lower than the ratio for a reference virus. However, ratios were stable in individual seroconversions over time. These data demonstrate that RT activity can be used to quantitate plasma virus load and provide evidence of different levels of virion-associated RT among HIV-1-infected persons.
引用
收藏
页码:1221 / 1229
页数:9
相关论文
共 40 条
[1]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[2]   Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription [J].
Arts, EJ ;
Wainberg, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :527-540
[3]   ANALYSIS AND GENOTYPING OF PCR PRODUCTS OF THE AMPLICOR HIV-1 KIT [J].
BARLOW, KL ;
TOSSWILL, JHC ;
CLEWLEY, JP .
JOURNAL OF VIROLOGICAL METHODS, 1995, 52 (1-2) :65-74
[4]  
Boni J, 1996, J MED VIROL, V49, P23, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt
[5]  
23::AID-JMV4&gt
[6]  
3.0.CO
[7]  
2-M
[8]  
BOUINBAIAR AS, 1991, NATURE, V349, P111
[9]   ANALYSIS OF MUTATIONS AT POSITION-184 IN REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
BOYER, PL ;
HUGHES, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1624-1628
[10]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969